tetano
Editor, Senior Moderator
Aging Dis
. 2020 Oct 1;11(5):1069-1081.
doi: 10.14336/AD.2020.0630. eCollection 2020 Oct.
Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study
Zhichao Feng[SUP] 1 2 [/SUP], Jennifer Li[SUP] 3 [/SUP], Shanhu Yao[SUP] 1 2 [/SUP], Qizhi Yu[SUP] 4 [/SUP], Wenming Zhou[SUP] 5 [/SUP], Xiaowen Mao[SUP] 6 [/SUP], Huiling Li[SUP] 1 [/SUP], Wendi Kang[SUP] 1 [/SUP], Xin Ouyang[SUP] 7 [/SUP], Ji Mei[SUP] 8 [/SUP], Qiuhua Zeng[SUP] 9 [/SUP], Jincai Liu[SUP] 10 [/SUP], Xiaoqian Ma[SUP] 1 2 [/SUP], Pengfei Rong[SUP] 1 2 [/SUP], Wei Wang[SUP] 1 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic associated with a high mortality. Our study aimed to determine the clinical risk factors associated with disease progression and prolonged viral shedding in patients with COVID-19. Consecutive 564 hospitalized patients with confirmed COVID-19 between January 17, 2020 and February 28, 2020 were included in this multicenter, retrospective study. The effects of clinical factors on disease progression and prolonged viral shedding were analyzed using logistic regression and Cox regression analyses. 69 patients (12.2%) developed severe or critical pneumonia, with a higher incidence in the elderly and in individuals with underlying comorbidities, fever, dyspnea, and laboratory and imaging abnormalities at admission. Multivariate logistic regression analysis indicated that older age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02-1.06), hypertension without receiving angiotensinogen converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) therapy (OR, 2.29; 95% CI, 1.14-4.59), and chronic obstructive pulmonary disease (OR, 7.55; 95% CI, 2.44-23.39) were independent risk factors for progression to severe or critical pneumonia. Hypertensive patients without receiving ACEI/ARB therapy showed higher lactate dehydrogenase levels and computed tomography (CT) lung scores at about 3 days after admission than those on ACEI/ARB therapy. Multivariate Cox regression analysis revealed that male gender (hazard ratio
, 1.22; 95% CI, 1.02-1.46), receiving lopinavir/ritonavir treatment within 7 days from illness onset (HR, 0.75; 95% CI, 0.63-0.90), and receiving systemic glucocorticoid therapy (HR, 1.79; 95% CI, 1.46-2.21) were independent factors associated with prolonged viral shedding. Our findings presented several potential clinical factors associated with developing severe or critical pneumonia and prolonged viral shedding, which may provide a rationale for clinicians in medical resource allocation and early intervention.
Keywords: Viral pneumonia; coronavirus disease 2019; disease progression; risk factors; viral shedding.
. 2020 Oct 1;11(5):1069-1081.
doi: 10.14336/AD.2020.0630. eCollection 2020 Oct.
Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study
Zhichao Feng[SUP] 1 2 [/SUP], Jennifer Li[SUP] 3 [/SUP], Shanhu Yao[SUP] 1 2 [/SUP], Qizhi Yu[SUP] 4 [/SUP], Wenming Zhou[SUP] 5 [/SUP], Xiaowen Mao[SUP] 6 [/SUP], Huiling Li[SUP] 1 [/SUP], Wendi Kang[SUP] 1 [/SUP], Xin Ouyang[SUP] 7 [/SUP], Ji Mei[SUP] 8 [/SUP], Qiuhua Zeng[SUP] 9 [/SUP], Jincai Liu[SUP] 10 [/SUP], Xiaoqian Ma[SUP] 1 2 [/SUP], Pengfei Rong[SUP] 1 2 [/SUP], Wei Wang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33014523
- PMCID: PMC7505267
- DOI: 10.14336/AD.2020.0630
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic associated with a high mortality. Our study aimed to determine the clinical risk factors associated with disease progression and prolonged viral shedding in patients with COVID-19. Consecutive 564 hospitalized patients with confirmed COVID-19 between January 17, 2020 and February 28, 2020 were included in this multicenter, retrospective study. The effects of clinical factors on disease progression and prolonged viral shedding were analyzed using logistic regression and Cox regression analyses. 69 patients (12.2%) developed severe or critical pneumonia, with a higher incidence in the elderly and in individuals with underlying comorbidities, fever, dyspnea, and laboratory and imaging abnormalities at admission. Multivariate logistic regression analysis indicated that older age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02-1.06), hypertension without receiving angiotensinogen converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) therapy (OR, 2.29; 95% CI, 1.14-4.59), and chronic obstructive pulmonary disease (OR, 7.55; 95% CI, 2.44-23.39) were independent risk factors for progression to severe or critical pneumonia. Hypertensive patients without receiving ACEI/ARB therapy showed higher lactate dehydrogenase levels and computed tomography (CT) lung scores at about 3 days after admission than those on ACEI/ARB therapy. Multivariate Cox regression analysis revealed that male gender (hazard ratio
, 1.22; 95% CI, 1.02-1.46), receiving lopinavir/ritonavir treatment within 7 days from illness onset (HR, 0.75; 95% CI, 0.63-0.90), and receiving systemic glucocorticoid therapy (HR, 1.79; 95% CI, 1.46-2.21) were independent factors associated with prolonged viral shedding. Our findings presented several potential clinical factors associated with developing severe or critical pneumonia and prolonged viral shedding, which may provide a rationale for clinicians in medical resource allocation and early intervention.
Keywords: Viral pneumonia; coronavirus disease 2019; disease progression; risk factors; viral shedding.